Frozen gloves and socks during paclitaxel or docetaxel are meant to narrow blood vessels in the hands and feet, reducing local exposure to chemotherapy. It is an appealing prevention strategy for neuropathy because it is drug-free and limited to infusion time. The signal is promising. The certainty is not there yet.
Evidence at a glance
- Studied population: primarily people with breast cancer receiving taxane chemotherapy, especially weekly paclitaxel.
- Intervention: frozen gloves and socks or controlled cooling, often started 15 minutes before infusion and continued until 15 minutes afterward.
- Meaningful benefit: pooled studies suggest fewer cases of neuropathy during and at the end of chemotherapy.
- Negative finding: a randomized breast-cancer trial did not improve its primary sensory-neuropathy outcome, and cold intolerance caused frequent interruptions.
- Boundary: cooling is preventive support; it does not treat established neuropathy or improve cancer control.
Why studies point in different directions
A well-known self-controlled study placed a frozen glove and sock on one side of the body in 40 patients receiving weekly paclitaxel 80 mg/m². Cooling ran for 90 minutes—15 minutes before treatment, through the one-hour infusion and 15 minutes after. The cooled side developed fewer objective and patient-reported neuropathy findings. The clever within-person design reduces some variability, but one side of the body is not fully independent of the other, and neither patients nor clinicians can be blinded to cold.
A separate randomized trial enrolled 46 people with early or locally advanced breast cancer receiving 12 weekly paclitaxel doses; 38 were evaluable. It used gloves and socks cooled to approximately −20 to −10°C for the same 90-minute window. The primary sensory-neuropathy result two weeks after treatment was negative. Some later motor and autonomic measures favored cooling, but benefits were inconsistent, and 81% of participants interrupted cooling at least once because of cold intolerance.
A 2024 meta-analysis pooling randomized and nonrandomized studies found lower neuropathy incidence midway through treatment and at its completion. Yet temperature, equipment, chemotherapy schedules and neuropathy scales varied substantially. ASCO’s CIPN guideline emphasizes that no preventive medication has established benefit. A large ongoing phase III trial is comparing cooling plus compression with compression strategies, a sign that the field still needs confirmation.
Cold is not automatically harmless
Most reports describe temporary discomfort, redness, numbness or tingling rather than serious injury, but frostbite remains a concern if devices are too cold or poorly monitored. Trials commonly exclude Raynaud disease; extra caution is reasonable with peripheral vascular disease, cold agglutinin disease, impaired skin sensation or broken skin. Cooling should be clinic-supervised, with the skin checked and the device removed for severe pain, color change or burning.
Questions for the care team
- Does your infusion center offer a standardized limb-cooling protocol for my taxane?
- Do I have circulation or cold-sensitivity risks that make cooling unsafe?
- How will my skin and comfort be monitored during treatment?
- What neuropathy symptoms should prompt an early dose or schedule discussion?
Explore the Missing Script evidence library, and follow the podcast, coming soon. This article is educational and does not replace individualized medical care.
